Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Association of UDP-glucuronosyltransferase 1A9 polymorphisms with adverse reactions to catechol-O-methyltransferase inhibitors in Parkinson's disease patients.

European journal of clinical pharmacology - 1 Nov 2012

Ferrari Marco, Martignoni Emilia, Blandini Fabio, Riboldazzi Giulio, Bono Giorgio, Marino Franca, Cosentino Marco

Abstract excerpt

PURPOSE: To investigate the association between adverse reactions to catechol-O-methyltransferase (COMT) inhibitors and the UDP-glucuronosyltransferase 1A9 genotypes UGT1A9*1b and UGT1A9*3a, which were previously identified in individual cases of COMT inhibitor-induced toxicity. METHODS: The study included 52 Parkinson's disease (PD) patients on COMT inhibitors without evidence of adverse reactions and 11 PD...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antiparkinson Agents
Share to Enzyme Inhibitors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Glucuronosyltransferase

Share to Hospitals, University

Share to Parkinson Disease

Share to Real-Time Polymerase Chain Reaction

Share to UDP-Glucuronosyltransferase 1A9

Source

Identifiers

PMID: 22527346
DOI: 10.1007/s00228-012-1281-y

Genes

COMT

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Association of UDP-glucuronosyltransferase 1A9 polymorphisms with adverse reactions to catechol-O-methyltransferase inhibitors in Parkinson's disease patients.PMID 22527346Read ↗

Two patients with COMT inhibitor-induced hepatic dysfunction and UGT1A9 genetic polymorphism.Semantic proximity Read ↗

Association of Catechol-O-Methyltransferase and monoamine oxidase B gene polymorphisms with motor complications in parkinson's disease in a Chinese population.Semantic proximity Read ↗

Association between catechol-O-methyltransferase gene polymorphisms and wearing-off and dyskinesia in Parkinson's disease.Semantic proximity Read ↗

The association of functional catechol-O-methyltransferase haplotypes with risk of Parkinson's disease, levodopa treatment response, and complicationsSemantic proximity Read ↗

Roles of functional catechol-O-methyltransferase genotypes in Chinese patients with Parkinson’s diseaseSemantic proximity Read ↗

Polymorphisms of Catechol-O-Methyl Transferase (COMT) Gene in Vulnerability to Levodopa-Induced Dyskinesia.Semantic proximity Read ↗

[Polymorphisms of catechol-O-methyltransferase and monoamine oxidase B genes among Chinese patients with Parkinson's disease].Semantic proximity Read ↗

Association of catechol-o-methyltransferase polymorphism (Val108/158Met) with Parkinson's disease: a meta-analysis.Semantic proximity Read ↗

Catechol-O-methyltransferase and Parkinson's disease.Semantic proximity Read ↗

Genetic variations in catechol-O-methyltransferase gene are associated with levodopa response variability in Chinese patients with Parkinson's disease.Semantic proximity Read ↗

Catechol-O-methyltransferase Val158Met and the risk of dyskinesias in Parkinson's disease.Semantic proximity Read ↗

Genetic polymorphism of catechol-O-methyltransferase and levodopa pharmacokinetic-pharmacodynamic pattern in patients with Parkinson's disease.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.